Neogenomics, Inc.
Could not find a ticker for this position, may be a filing error
A laboratory that focuses exclusively on cancer testing, helping oncologists and pathologists diagnose tumors and choose treatments through genetic and molecular analysis. Founded in 2001 in Fort Myers, Florida, by a pathologist and a healthcare executive, it has grown into one of the largest oncology-focused reference labs in the United States. The name blends "neo" — Greek for "new" — with "genomics," a nod to the modern genetic techniques at its core.
0.25% Convertible Senior Notes due 2028
Sold 15.00M
Bought 84.0K
Bought 275.0K
Granted 83.3K · Sold 1.30M
Granted 413.5K · Sold 543.7K
Granted 3.65M · Bought 21.7K · Sold 1.46M
Granted 481.6K · Sold 2.59M
Granted 707.7K
Granted 351.1K · Bought 17.0K
Granted 1.08M · Bought 6.5K · Sold 951.1K
Granted 929.3K · Bought 7.0K · Sold 751.5K
Granted 233.0K · Bought 40.0K
Granted 164.1K · Bought 36.8K
Granted 336.6K · Sold 142.6K
Granted 92.8K
Granted 257.7K · Bought 5.7K · Sold 22.1K
Granted 570.0K · Bought 14.5K · Sold 538.2K
Granted 10.5K
Granted 152.6K · Sold 100.0K
Granted 147.1K
Granted 101.6K · Bought 30.0K
Granted 148.5K
Granted 151.0K · Sold 20.2K
Granted 123.7K
Granted 150.0K · Sold 244.7K
Granted 123.3K · Sold 38.4K
Granted 122.3K · Bought 20.0K · Sold 34.7K
Granted 24.7K
Granted 71.4K · Bought 4.0K
Granted 67.1K · Bought 5.0K
Granted 57.0K · Bought 10.0K
Granted 64.1K · Sold 254.9K
Granted 92.3K · Bought 6.4K · Sold 31.5K
Granted 22.3K · Sold 2.3K
Granted 146.5K · Sold 95.3K
Granted 46.7K · Bought 4.5K
Granted 60.0K · Sold 9.8K
Granted 275.1K · Sold 204.2K
Granted 80.0K · Sold 66.5K
Granted 43.2K
Granted 41.3K
Granted 70.6K · Bought 22.0K · Sold 143.7K
Granted 28.9K
Granted 30.2K
Granted 32.0K
Granted 17.1K
Granted 23.6K
Granted 23.0K
Granted 21.3K
Granted 17.2K
Granted 10.9K
Granted 45.0K · Sold 45.0K
Granted 5.9K
Granted 298.3K · Sold 298.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| General Electric Co +1 co-filerFormer 10% Owner · 2 transactions | — | 10.84Mas of Dec 2018 | — | — | 15.00M |
| Clearman Stephen J +4 co-filers10% owner · 3 transactions | — | 4.85Mas of Jun 2012 | — | 84.0K | — |
| Clearman Stephen J +4 co-filers10% owner · 2 transactions | — | 4.49Mas of May 2012 | — | 275.0K | — |
| Aspen Select Healthcare LP +1 co-filer10% owner, Executive VP of Finance · 22 transactions | — | 4.10Mas of Nov 2015 | 83.3K | — | 1.30M |
| Dent Michael TDirector · 15 transactions | — | 3.35Mas of Dec 2014 | 413.5K | — | 543.7K |
| Van Oort Douglas MDirector · 54 transactions | — | 2.48Mas of Aug 2021 | 3.65M | 21.7K | 1.46M |
| Jones Steven CDirector · 66 transactions | — | 1.38Mas of Jan 2021 | 481.6K | — | 2.59M |
| Smith Christopher MChief Executive Officer · 7 transactions | — | 641.6Kas of Feb 2025 | 707.7K | — | — |
| Mallon MarkChief Executive Officer, Director · 4 transactions | — | 368.1Kas of Mar 2022 | 351.1K | 17.0K | — |
| Shovlin Robert J.President, Clinical Services · 36 transactions | — | 266.6Kas of May 2021 | 1.08M | 6.5K | 951.1K |
| Cardoza GeorgePresident & COO, Lab Ops · 32 transactions | — | 264.2Kas of Mar 2022 | 929.3K | 7.0K | 751.5K |
| Sherman Jeffrey ScottChief Financial Officer · 17 transactions | — | 220.0K | 233.0K | 40.0K | — |
| Zook Anthony P.Chief Executive Officer, Director · 7 transactions | — | 209.0K | 164.1K | 36.8K | — |
| Bonello WilliamChief Financial Officer · 29 transactions | — | 191.5Kas of Apr 2022 | 336.6K | — | 142.6K |
| Robison William JDirector · 6 transactions | — | 176.1Kas of May 2017 | 92.8K | — | — |
| Stone WarrenPres & Chief Operating Officer · 27 transactions | — | 167.8K | 257.7K | 5.7K | 22.1K |
| Albitar MaherChief Medical Officer · 11 transactions | — | 166.0Kas of May 2017 | 570.0K | 14.5K | 538.2K |
| Peterson Peter MDirector · 1 transaction | — | 163.9Kas of Jun 2012 | 10.5K | — | — |
| Brown Douglas MatthewChief Strategy Officer · 8 transactions | — | 158.7Kas of Apr 2022 | 152.6K | — | 100.0K |
| Gilbert Halley EChief Legal Officer · 4 transactions | — | 147.4Kas of Mar 2022 | 147.1K | — | — |
| Hannah Alison L.Director · 15 transactions | — | 131.0Kas of Jun 2025 | 101.6K | 30.0K | — |
| Sikri VishalPresident Advanced Diagnostics · 3 transactions | — | 128.9Kas of Feb 2024 | 148.5K | — | — |
| Weiss Lawrence MartinChief Medical Officer · 12 transactions | — | 112.5Kas of Apr 2021 | 151.0K | — | 20.2K |
| Harris MelodyChf Ops Off, Pres, Informatics · 7 transactions | — | 109.8Kas of Feb 2025 | 123.7K | — | — |
| Gasparini Robert PChief Science Officer · 26 transactions | — | 108.4Kas of May 2014 | 150.0K | — | 244.7K |
| Olivo Alicia CEVP, GC & Business Development · 33 transactions | — | 93.6K | 123.3K | — | 38.4K |
| Tetrault LYNN A.Director · 26 transactions | — | 93.1K | 122.3K | 20.0K | 34.7K |
| Kulkarni ShashikantChief Scientific Officer · 2 transactions | — | 82.7Kas of Apr 2023 | 24.7K | — | — |
| Kanovsky Stephen MDirector · 8 transactions | — | 75.4K | 71.4K | 4.0K | — |
| Kelly Michael AaronDirector · 7 transactions | — | 72.1K | 67.1K | 5.0K | — |
| Perez David BrianDirector · 5 transactions | — | 67.0K | 57.0K | 10.0K | — |
| Hipp Raymond RDirector · 20 transactions | — | 66.8Kas of Nov 2020 | 64.1K | — | 254.9K |
| Crowther Bruce KDirector · 19 transactions | — | 65.1Kas of Aug 2023 | 92.3K | 6.4K | 31.5K |
| Pedulla Denise EGeneral Counsel · 6 transactions | — | 56.3Kas of Mar 2021 | 22.3K | — | 2.3K |
| Horel Robert H.Vice President GM PathLogic · 11 transactions | — | 51.2Kas of Dec 2015 | 146.5K | — | 95.3K |
| Gunn NeilDirector · 4 transactions | — | 51.2K | 46.7K | 4.5K | — |
| McKenzie Kathryn BChief Sustainability/Risk Ofcr · 12 transactions | — | 49.4Kas of Jan 2022 | 60.0K | — | 9.8K |
| Balliet JenniferVP and Chief Culture Officer · 43 transactions | — | 48.6Kas of Dec 2021 | 275.1K | — | 204.2K |
| Brodie Steven G.VP - Pharma Operations · 8 transactions | — | 46.0Kas of Oct 2018 | 80.0K | — | 66.5K |
| Sholehvar DavidPresident, Clinical Services · 2 transactions | — | 43.2Kas of Aug 2022 | 43.2K | — | — |
| Morris ClivePresident of Inivata · 2 transactions | — | 41.3Kas of Dec 2021 | 41.3K | — | — |
| Johnson Kevin CDirector · 21 transactions | — | 37.4Kas of Dec 2021 | 70.6K | 22.0K | 143.7K |
| Wallar Gina MPresident, Pharma Services · 4 transactions | — | 33.4Kas of Mar 2022 | 28.9K | — | — |
| Williams FeliciaDirector · 2 transactions | — | 30.2K | 30.2K | — | — |
| Dieter Cynthia JChief Accounting Officer · 11 transactions | — | 29.8Kas of Mar 2023 | 32.0K | — | — |
| Aunan Greg DChief Accounting Officer · 9 transactions | — | 25.2K | 17.1K | — | — |
| Floegel ElizabethDirector · 2 transactions | — | 23.6Kas of Jun 2025 | 23.6K | — | — |
| Green Marjorie CDirector · 1 transaction | — | 23.0K | 23.0K | — | — |
| Stahler Rachel ADirector · 3 transactions | — | 21.3Kas of Jun 2022 | 21.3K | — | — |
| Daly DavidDirector · 2 transactions | — | 17.2Kas of Jun 2022 | 17.2K | — | — |
| Virag SharonChief Financial Officer · 1 transaction | — | 10.9Kas of Mar 2019 | 10.9K | — | — |
| Smits Mark WChief Commercial Officer · 2 transactions | — | 6.7Kas of May 2011 | 45.0K | — | 45.0K |
| Kenny John P.Director · 1 transaction | — | 5.9K | 5.9K | — | — |
| Ross Steven ACIO · 15 transactions | — | 4.5Kas of May 2018 | 298.3K | — | 298.3K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -24.28M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.